Dermata Therapeutics has received a notice of allowance for a new patent related to compositions for treating skin conditions, indicating a significant step in their intellectual property development. The anticipated granting of this patent could strengthen their market position and enhance their ability to capture future revenue from innovative treatment solutions.
DRMA's Xyngari trial met primary endpoints with significant results. The product showed safety with minimal adverse events. Xyngari's once-weekly dosing may improve patient compliance. DRMA stock surged 48.1% following positive trial outcomes. A second Phase 3 trial is planned for 2025.
